Send the following on WhatsApp
Continue to Chathttps://www.zonebourse.com/cours/action/EIRGENIX-INC-45428622/actualite/EirGenix-Inc-acheve-l-essai-clinique-de-phase-1-EGC101-de-son-deuxieme-biosimilaire-EG1206A-pou-43721407/?utm_source=whatsapp&utm_medium=social&utm_campaign=share